BIIB – Biogen Inc.
BIIB — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
2.96
Margin Of Safety %
22
Put/Call OI Ratio
0.99
EPS Next Q Diff
4.65
EPS Last/This Y
6.87
EPS This/Next Y
0.53
Price
183.82
Target Price
209.44
Analyst Recom
2.28
Performance Q
4.26
Upside
-37.7%
Beta
0.14
Ticker: BIIB
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | BIIB | 191.88 | 0.77 | 0.29 | 51550 |
| 2026-03-02 | BIIB | 187.99 | 0.77 | 0.45 | 51248 |
| 2026-03-03 | BIIB | 183.93 | 0.77 | 0.77 | 51338 |
| 2026-03-04 | BIIB | 189.78 | 0.77 | 0.48 | 51541 |
| 2026-03-05 | BIIB | 188.08 | 0.77 | 0.87 | 51671 |
| 2026-03-06 | BIIB | 184.73 | 0.77 | 0.87 | 51647 |
| 2026-03-09 | BIIB | 188.33 | 0.77 | 2.22 | 50716 |
| 2026-03-10 | BIIB | 188.57 | 0.78 | 0.31 | 51113 |
| 2026-03-11 | BIIB | 190.34 | 0.77 | 0.04 | 51298 |
| 2026-03-12 | BIIB | 184.15 | 0.77 | 0.43 | 51557 |
| 2026-03-13 | BIIB | 184.9 | 0.77 | 0.61 | 51557 |
| 2026-03-17 | BIIB | 185.23 | 0.78 | 0.74 | 53010 |
| 2026-03-18 | BIIB | 182.25 | 0.78 | 0.45 | 53286 |
| 2026-03-19 | BIIB | 183.45 | 0.77 | 2.71 | 53488 |
| 2026-03-20 | BIIB | 181.7 | 0.79 | 4.08 | 54068 |
| 2026-03-23 | BIIB | 183.69 | 0.94 | 3.30 | 37677 |
| 2026-03-24 | BIIB | 183.95 | 0.94 | 0.34 | 38068 |
| 2026-03-25 | BIIB | 189.16 | 0.99 | 3.23 | 39807 |
| 2026-03-26 | BIIB | 191.18 | 1.04 | 0.17 | 41993 |
| 2026-03-27 | BIIB | 183.61 | 0.99 | 1.27 | 42831 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | BIIB | 191.85 | 0.8 | 814.3 | 15.69 |
| 2026-03-02 | BIIB | 188.01 | 0.8 | 494.9 | 15.69 |
| 2026-03-03 | BIIB | 183.94 | 0.8 | 490.6 | 15.69 |
| 2026-03-04 | BIIB | 189.91 | 0.8 | 606.2 | 15.69 |
| 2026-03-05 | BIIB | 188.08 | 0.8 | 516.6 | 15.69 |
| 2026-03-06 | BIIB | 184.83 | 0.8 | 500.5 | 15.69 |
| 2026-03-09 | BIIB | 188.34 | 0.8 | 577.8 | 15.69 |
| 2026-03-10 | BIIB | 188.50 | 0.8 | 540.5 | 15.69 |
| 2026-03-11 | BIIB | 190.35 | 0.8 | 559.7 | 15.69 |
| 2026-03-12 | BIIB | 184.77 | 0.8 | 473.2 | 15.69 |
| 2026-03-13 | BIIB | 181.51 | 0.8 | 498.3 | 15.69 |
| 2026-03-17 | BIIB | 185.29 | 0.8 | 561.3 | 15.69 |
| 2026-03-18 | BIIB | 182.20 | 0.8 | 501.8 | 15.69 |
| 2026-03-19 | BIIB | 183.45 | 0.8 | 192.3 | 15.69 |
| 2026-03-20 | BIIB | 181.46 | 0.8 | 162.6 | 15.69 |
| 2026-03-23 | BIIB | 183.70 | 0.8 | 203.3 | 15.70 |
| 2026-03-24 | BIIB | 183.91 | 0.8 | 183.6 | 15.70 |
| 2026-03-25 | BIIB | 189.12 | 0.8 | 232.1 | 15.70 |
| 2026-03-26 | BIIB | 191.16 | 0.8 | 200.0 | 15.70 |
| 2026-03-27 | BIIB | 183.82 | 0.8 | 111.7 | 15.70 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | BIIB | -1.15 | 2.71 | 3.10 |
| 2026-03-02 | BIIB | -1.15 | 4.36 | 3.10 |
| 2026-03-03 | BIIB | -1.00 | 4.36 | 3.10 |
| 2026-03-04 | BIIB | -1.00 | 4.36 | 3.10 |
| 2026-03-05 | BIIB | -1.00 | 4.36 | 3.10 |
| 2026-03-06 | BIIB | -1.00 | 4.36 | 3.10 |
| 2026-03-09 | BIIB | -1.00 | 4.36 | 3.10 |
| 2026-03-10 | BIIB | -1.00 | 4.36 | 3.10 |
| 2026-03-11 | BIIB | -1.00 | 4.36 | 2.87 |
| 2026-03-12 | BIIB | -1.00 | 4.36 | 2.87 |
| 2026-03-13 | BIIB | -1.00 | 4.36 | 2.87 |
| 2026-03-17 | BIIB | -1.00 | 4.95 | 2.87 |
| 2026-03-18 | BIIB | -1.00 | 4.95 | 2.87 |
| 2026-03-19 | BIIB | -1.00 | 4.95 | 2.87 |
| 2026-03-20 | BIIB | -1.00 | 4.95 | 2.87 |
| 2026-03-23 | BIIB | -1.00 | 4.43 | 2.87 |
| 2026-03-24 | BIIB | -1.00 | 4.43 | 2.87 |
| 2026-03-25 | BIIB | -1.00 | 4.43 | 2.96 |
| 2026-03-26 | BIIB | -1.00 | 4.43 | 2.96 |
| 2026-03-27 | BIIB | -1.00 | 4.43 | 2.96 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.33
Avg. EPS Est. Current Quarter
3.04
Avg. EPS Est. Next Quarter
4.32
Insider Transactions
-1
Institutional Transactions
4.43
Beta
0.14
Average Sales Estimate Current Quarter
2239
Average Sales Estimate Next Quarter
2395
Fair Value
223.47
Quality Score
86
Growth Score
51
Sentiment Score
98
Actual DrawDown %
60.8
Max Drawdown 5-Year %
-72.7
Target Price
209.44
P/E
20.88
Forward P/E
11.36
PEG
2.64
P/S
2.83
P/B
1.48
P/Free Cash Flow
13.16
EPS
8.81
Average EPS Est. Cur. Y
15.7
EPS Next Y. (Est.)
16.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
13.56
Relative Volume
0.72
Return on Equity vs Sector %
-20.3
Return on Equity vs Industry %
-29.6
EPS 1 7Days Diff
EPS 1 30Days Diff
0.03
EBIT Estimation
111.7
◆
BIIB
Healthcare
$183.84
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
47.2
Range 1M
26.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
3.1%
EPS NY
2.7%
52W%
79.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+16.7% upside
Upside
+16.7%
Quality
86
MoS
22%
Biogen Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 7500
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
BIIB
Latest News
—
Caricamento notizie per BIIB…
stock quote shares BIIB – Biogen Inc. Stock Price stock today
news today BIIB – Biogen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BIIB – Biogen Inc. yahoo finance google finance
stock history BIIB – Biogen Inc. invest stock market
stock prices BIIB premarket after hours
ticker BIIB fair value insiders trading